Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Kestens C, et al. Among authors: van tuyl ba. Clin Gastroenterol Hepatol. 2013 Jul;11(7):826-31. doi: 10.1016/j.cgh.2013.01.012. Epub 2013 Jan 29. Clin Gastroenterol Hepatol. 2013. PMID: 23376000
Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RC, van Tuyl BA, van der Meulen-de Jong AE, Pierik M, Siersema PD, van Oijen MG, Fidder HH. van der Have M, et al. Among authors: van tuyl ba. J Crohns Colitis. 2016 May;10(5):549-55. doi: 10.1093/ecco-jcc/jjw002. Epub 2016 Jan 6. J Crohns Colitis. 2016. PMID: 26738757 Free PMC article.
Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events.
Asscher VER, van der Vliet Q, van der Aalst K, van der Aalst A, Brand EC, van der Meulen-de Jong AE, Oldenburg B, Pierik MJ, van Tuyl B, Mahmmod N, Maljaars PWJ, Fidder HH; Dutch ICC. Asscher VER, et al. Int J Colorectal Dis. 2020 Dec;35(12):2331-2338. doi: 10.1007/s00384-020-03716-6. Epub 2020 Aug 28. Int J Colorectal Dis. 2020. PMID: 32860081 Free PMC article.
Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
Ten Bokkel Huinink S, de Jong DC, Nieboer D, Thomassen D, Steyerberg EW, Dijkgraaf MGW, Bodelier AGL, West RL, Römkens TEH, Hoentjen F, Mallant RC, van Tuyl BAC, Mares WGN, Wolfhagen FHJ, Dijkstra G, Reijnders JGP, de Boer NK, Tan ACITL, van Boeckel PGA, Tack GJ, van Asseldonk DP, D'Haens GRAM, van der Woude CJ, Duijvestein M, de Vries AC. Ten Bokkel Huinink S, et al. Among authors: van tuyl bac. Eur J Gastroenterol Hepatol. 2022 Oct 1;34(10):983-992. doi: 10.1097/MEG.0000000000002403. Epub 2022 Aug 30. Eur J Gastroenterol Hepatol. 2022. PMID: 36062493
Corrigendum: Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RCH, van Tuyl BA, van der Meulen-de Jong AE, Pierik M, Siersema PD, van Oijen MGH, Fidder HH. van der Have M, et al. Among authors: van tuyl ba. J Crohns Colitis. 2018 Nov 15;12(11):1381. doi: 10.1093/ecco-jcc/jjy083. J Crohns Colitis. 2018. PMID: 29982408 Free PMC article. No abstract available.